Vertex Pharmaceuticals (VRTX) Cash from Restructuring (2009 - 2017)

Vertex Pharmaceuticals' Cash from Restructuring history runs 9 years deep, the most recent figure standing at -$2.1 million for Q4 2017.

• In Q4 2017, Cash from Restructuring fell 392.97% year-over-year to -$2.1 million; the TTM figure through Dec 2017 stood at -$6.0 million (up 19.38% YoY), while the FY2017 annual figure was -$6.0 million, up 19.38% from the prior year.
• Cash from Restructuring was -$2.1 million for Q4 2017 at Vertex Pharmaceuticals, up from -$2.8 million in the prior quarter.
• In the past five years, Cash from Restructuring ranged from a high of $36.6 million in Q3 2014 to a low of -$24.4 million in Q1 2015.
• Historically, Cash from Restructuring has averaged -$1.1 million across 5 years, with a median of -$1.6 million in 2015.
• Biggest YoY gain for Cash from Restructuring was 796.18% in 2014; the steepest drop was 1099.75% in 2014.
• A 5-year view of Cash from Restructuring shows it stood at $2.2 million in 2013, then sank by 540.05% to -$9.7 million in 2014, then soared by 74.96% to -$2.4 million in 2015, then soared by 129.7% to $725000.0 in 2016, then plunged by 392.97% to -$2.1 million in 2017.
• The last three Cash from Restructuring figures came in at -$2.1 million (Q4 2017), -$2.8 million (Q3 2017), and -$1.4 million (Q2 2017), per Business Quant data.